Related Experiment Video
Updated: May 5, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Etomidate in Severe Cushing Syndrome: A Systematic Review.
Dimuthu Tharanga Muthukuda1, Kamani Dhanushka Liyanaarachchi2, Kushalee Poornima Jayawickreme3
1Consultant Endocrinologist, Sri Jayewardenepura General Hospital, Colombo 10250, Sri Lanka.
Etomidate is a safe and effective intravenous treatment for severe Cushing syndrome, particularly in critical care settings. This review highlights its efficacy in rapidly reducing cortisol levels, improving patient outcomes.
Area of Science:
- Endocrinology
- Critical Care Medicine
- Pharmacology
Background:
- Severe Cushing syndrome necessitates urgent intervention.
- Etomidate is the sole intravenous option for hypercortisolism, crucial for critically ill patients unable to take oral medications.
Purpose of the Study:
- To systematically review and meta-analyze the efficacy and safety of etomidate in treating severe Cushing syndrome.
Main Methods:
- A systematic review and meta-analysis of 36 articles, including 76 clinical cases and 78 episodes of etomidate use.
- Data reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Main Results:
- Etomidate was safely administered to a wide age range (2 months to 82 years).
- Faster cortisol reduction observed with higher baseline cortisol, prior bolus dose, and higher initial infusion rates.
- Etomidate as first-line therapy and in ICU settings showed more rapid cortisol reduction.
Conclusions:
- Etomidate is effective and safe for lowering cortisol levels in Cushing syndrome.
- Standardized guidelines for etomidate use in diverse clinical settings are needed to optimize safety and efficacy.
More Related Videos
06:04Objective Nociceptive Assessment in Ventilated ICU Patients: A Feasibility Study Using Pupillometry and the Nociceptive Flexion Reflex
Published on: July 4, 2018
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Stages of General Anesthesia
Parenteral Anesthetics: Overview
Inhalational Anesthetics: Overview
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Electroconvulsive Therapy